Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1

Annals of Hematology

Volumn 93, Issue 2, 2014, Pages 255-265

  Lo, Rico K H ^a   Kwong, Yok Lam ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Arsenic trioxide; Cyclin D1; Mantle cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CCND1 PROTEIN, HUMAN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEASOME; RETINOBLASTOMA PROTEIN;

APOPTOSIS; BIOSYNTHESIS; CELL CYCLE; CLINICAL TRIAL; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; LYMPHOMA, MANTLE-CELL; MALE; METABOLISM; PHOSPHORYLATION; PROTEIN DEGRADATION; TUMOR CELL LINE; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; OXIDES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION, GENETIC; UBIQUITINATION;

EID: 84895059940     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1866-2     Document Type: Article

References (34)

1. Swerdlow SH, Campo E, Seto M, Müller-Hermelink HK (2008) Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, pp 229-232
2. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89(11):3909-3918
3. Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC, Croce CM (1984) Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 224(4656):1403-1406
4. Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM (1985) Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315(6017):340-343
5. Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672-1677
6. Pérez-Galán P, Dreyling M, Wiestner A (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117(1):26-38
7. Guo Y, Stacey DW, Hitomi M (2002) Post-transcriptional regulation of cyclin D1 expression during G2 phase. Oncogene 21(49):7545-7556
8. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M, Stacey DW (2005) Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 24(16):2599-2612
9. Diehl JA, Zindy F, Sherr CJ (1997) Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11(8):957-972
10. Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12(22):3499-3511
11. Alt JR, Cleveland JL, Hannink M, Diehl JA (2000) Phosphorylation- dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14(24):3102-3114
12. Kwak YT, Li R, Becerra CR, Tripathy D, Frenkel EP, Verma UN (2005) IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. J Biol Chem 280(40):33945-33952
13. Tallman MS, Altman JK (2009) How I treat acute promyelocytic leukemia. Blood 114(25):5126-5135
14. Chen SJ, Zhou GB, Zhang XW, Mao JH, de Thé H, Chen Z (2011) From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 117(24):6425-6437
15. Au WY, Ma SK, Chung LP, Chim CS, Kwong YL (2002) Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease. Ann Hematol 81(11):659-661
16. Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS (2009) Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol 27(1):11-16
17. Fujimuro M, Yokosawa H (2005) Production of antipolyubiquitin monoclonal antibodies and their use for characterization and isolation of polyubiquitinated proteins. Methods Enzymol 399:75-86
18. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385(6616):544-548
19. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559):785-789
20. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR (1993) Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12(2):803-808
21. Lesort M, Jope RS, Johnson GV (1999) Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J Neurochem 72(2):576-584
22. Fan G, Ballou LM, Lin RZ (2003) Phospholipase C-independent activation of glycogen synthase kinase-3beta and C-terminal Src kinase by Galphaq. J Biol Chem 278(52):52432-52436
23. Sayas CL, Ariaens A, Ponsioen B, Moolenaar WH (2006) GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. Mol Biol Cell 17(4):1834-1844
24. Hartigan JA, Johnson GV (1999) Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J Biol Chem 274(30):21395-21401
25. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749-759
26. Ling L, Cao Z, Goeddel DV (1998) NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci U S A 95(7):3792-3797
27. Malinin NL, Boldin MP, Kovalenko AV, Wallach D (1997) MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 385(6616):540-544
28. Ciechanover A (1998) The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17(24):7151-7160
29. Hicke L (2001) Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2(3):195-201
30. Jung HJ, Chen Z, McCarty N (2012) Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. Am J Hematol 87(12):1057-1064
31. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328(5975):240-243
32. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A, Duprez E, Pandolfi PP, Puvion E, Freemont P, de The H (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193(12):1361-1371
33. Au WY, Tam S, Fong BM, Kwong YL (2008) Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 112(9):3587-3590
34. Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, Lau JS, Kwong YL (2011) Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood 118(25):6535-6543